Comparative study of 18F-FAPI-04 and 18F-FDG PET/CT in the initial staging and postoperative metastasis detection of gastric cancer

doi:10.4251/wjgo.120559

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 9

This Article

(12)

(11)

(0)

(126)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Sep 15, 2026; 18(9): 120559
Published online Sep 15, 2026. doi: 10.4251/wjgo.120559

Table 2 Comparison of ¹⁸F-fibroblast activation protein inhibitor-04 and ¹⁸F-fluorodeoxyglucos uptake in various lesions

Descriptions of lesions	¹⁸F-FAPI-04 PET/CT				¹⁸F-FDG PET/CT				P value FAPI/FDG
Descriptions of lesions	SUVmax	FTV (cm³)	TLF (SUVbw × cm³)	TBR	SUVmax	MTV (cm³)	TLG (SUVbw × cm³)	TBR	SUVmax	TBR	F/MTV	TLF/G
Primary GC	11.6 (10.5-19.3)	41.2 (17.9-69.9)	260.5 (131.6-363.1)	11.5 (10.5-17.4)	6.5 (5.0-8.1)	18.4 (8.6-27.9)	57.9 (30.9-126.8)	5.1 (4.6-7.4)	0.036	0.009	0.088	0.036
LNM	6.6 (4.4-10.6)	3.1 (0.8-3.4)	8.3 (2.6-20.9)	5.4 (4.2-9.2)	6.5 (3.8-10.5)	1.9 (0.5-3.3)	6.3 (2.1-16.2)	6.4 (4.5-9.6)	0.703	0.65	0.321	0.654
BM	11.1 (9.0-16.6)	6.4 (3.2-14.8)	27.7 (12.5-84.2)	10.4 (8.4-16.0)	5.5 (4.5-6.7)	2.4 (0.9-13.1)	9.5 (2.8-52.5)	5.6 (4.0-7.0)	< 0.001	< 0.001	0.128	0.045
PM	7.1 (4.7-10.0)	13.2 (3.4-25.5)	39.3 (16.2-76.8)	7.4 (5.8-9.7)	3.2 (0.0-3.9)	1.2 (0.0-1.8)	3.3 (0.0-5.3)	2.4 (0.0-3.9)	0.002	0.002	0.003	0.004
LM	8.4 (7.4-9.3)	15.2 (10.3-20.1)	67.6 (43.7-91.5)	9.8 (8.7-10.9)	8.2 (8.1-8.2)	8.0 (6.3-9.7)	35.3 (27.9-42.8)	7.4 (6.9-7.8)	N/A	N/A	N/A	N/A
LR	3.9 (NA)	7.8 (NA)	24.7 (NA)	8.1 (NA)	2.9 (NA)	1.2 (NA)	3.2 (NA)	1.2 (NA)	N/A	N/A	N/A	N/A

¹⁸F-FAPI-04: ¹⁸F-fibroblast activation protein inhibitor-04; PET/CT: Positron emission tomography/computed tomography; ¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose; FAPI: Fibroblast activation protein inhibitor; FDG: Fluorodeoxyglucose; SUVmax: Maximum standardized uptake value; FTV: Fibroblast activation protein inhibitor-avid tumor volume; TLF: Total lesion fibroblast activation protein expression; SUVbw: Standardized uptake value normalized to body weight; TBR: Tumor-to-background ratio; MTV: Fluorodeoxyglucose-derived metabolic tumor volume; TLG: Total lesion glycolysis; F/MTV: Fibroblast activation protein inhibitor-avid tumor volume/fluorodeoxyglucose-derived metabolic tumor volume; TLF/G: Total lesion fibroblast activation protein expression/total lesion glycolysis; GC: Gastric cancer; LR: Local recurrences; LNM: Lymph node metastases; BM: Bone metastases; LM: Liver metastases; PM: Peritoneal metastases; NA: Not available (data could not be calculated due to only 1 lesion in the local recurrences group); N/A: Not applicable (statistical comparisons were not performed for lesion types with fewer than 3 lesions i.e., liver metastases and local recurrences subgroups).

Full Size Table

Citation: Xue XQ, Li QB, Fu HT, Hou L, Wang R, Shi X, Yu CJ. Comparative study of ¹⁸F-FAPI-04 and ¹⁸F-FDG PET/CT in the initial staging and postoperative metastasis detection of gastric cancer. World J Gastrointest Oncol 2026; 18(9): 120559
URL: https://www.wjgnet.com/1948-5204/full/v18/i9/120559.htm
DOI: https://dx.doi.org/10.4251/wjgo.120559

Xue XQ, Li QB, Fu HT, Hou L, Wang R, Shi X, Yu CJ. Comparative study of ¹⁸F-FAPI-04 and ¹⁸F-FDG PET/CT in the initial staging and postoperative metastasis detection of gastric cancer. World J Gastrointest Oncol 2026; 18(9): 120559 [DOI: 10.4251/wjgo.120559]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.